{"ticker": {"uuid": "722285fe-98c3-49f4-9836-f9c4d773ce97", "symbol": "SVRA", "name": "Savara Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Join Class Action to Recover Losses from Savara Inc. (SVRA) - Contact Levi & Korsinsky Before November 7, 2025", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Savara Inc. (SVRA) on behalf of shareholders who suffered losses due to alleged securities fraud between March 4, 2024, and May 23, 2025. The lawsuit claims Savara made false statements and concealed issues ", "url": "https://www.natlawreview.com/press-releases/join-class-action-recover-losses-savara-inc-svra-contact-levi-korsinsky", "source_name": "The National Law Review", "published_at": "2026-07-14T17:42:44", "published_display": "14 Jul 2026 17:42", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Savara (SVRA) Stock May Trade At A Premium On Pipeline Expectations", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara stock. Thin-source profile holds the focus.", "summary": "Savara Inc. (SVRA) continues to focus on its rare-disease pipeline and Nasdaq listing, with its lead program being molgramostim inhalation therapy for autoimmune pulmonary alveolar proteinosis. Despite the absence of new market catalysts, the company's development pipeline and fi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/savara-stock-thin-source-profile-holds-the-focus/69715953", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:32:08", "published_display": "07 Jul 2026 16:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "This article displays the \"Price to earnings forward\" value for Savara, Inc. (NASDAQ: SVRA) on TradingView. It indicates that the period value and change are displayed, and states that the information is \"Made by humans.\"", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T10:09:34", "published_display": "05 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "This article provides a financial snapshot for Savara, Inc. (NASDAQ: SVRA), focusing on its enterprise value to EBIT forward. It indicates whether there have been changes in this period and by what percentage. The data is supported by various financial services and is presented v", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T23:40:34", "published_display": "04 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "This article displays the Enterprise Value to EBITDA forward for Savara, Inc. (NASDAQ: SVRA) on TradingView. It indicates that the market was closed at the time of viewing, with no trades reported. The content is primarily a data point without further analytical text.", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T05:11:11", "published_display": "04 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc focuses on respiratory drug development as investors watch clinical progress", "summary": "Savara Inc. is a clinical-stage biopharmaceutical company specializing in developing inhaled therapies for rare respiratory diseases. The company's strategy involves focusing on conditions with high unmet medical needs, pursuing orphan-drug designations, and advancing its pipelin", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/savara-inc-focuses-on-respiratory-drug-development-as-investors-watch/69682070", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T18:09:51", "published_display": "03 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "This article provides financial information for Savara, Inc. (NASDAQ: SVRA), specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section of a larger financial data display, indicating the period and value of this metric. It originates f", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T11:41:14", "published_display": "02 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "This page provides financial information for Savara, Inc. (NASDAQ: SVRA), specifically focusing on its price-to-sales forward metric. It appears to be a financial data snippet from TradingView, offering a quick overview of this particular financial ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T06:09:42", "published_display": "01 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "The article focuses on the enterprise value to revenue forward metric for Savara, Inc. (NASDAQ: SVRA). It appears to be a stub or a placeholder, as no specific financial data or analysis is presented in the provided content, only the title and navigation elements.", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T13:41:53", "published_display": "30 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline", "summary": "Levi & Korsinsky LLP has announced a class action lawsuit against Savara Inc. (NASDAQ:SVRA), reminding investors of the November 7, 2025 deadline to join. The lawsuit alleges that Savara made false and misleading statements between March 4, 2024, and May 23, 2025, regarding the r", "url": "https://www.natlawreview.com/press-releases/savara-inc-svra-class-action-lawsuit-levi-korsinsky-reminds-investors", "source_name": "The National Law Review", "published_at": "2026-06-30T06:39:11", "published_display": "30 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Notifies Savara Inc. (SVRA) Investors - Lead Plaintiff Deadline on November 7, 2025", "summary": "Levi & Korsinsky has announced a class action securities lawsuit against Savara Inc. (SVRA), urging investors who suffered losses between March 4, 2024, and May 23, 2025, to come forward by the lead plaintiff deadline of November 7, 2025. The lawsuit alleges that Savara made fals", "url": "https://natlawreview.com/press-releases/levi-korsinsky-notifies-savara-inc-svra-investors-lead-plaintiff-deadline", "source_name": "The National Law Review", "published_at": "2026-06-28T19:39:41", "published_display": "28 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Lawsuit Alert: Savara Inc. (SVRA) Investors - Contact Levi & Korsinsky Before November 7, 2025", "summary": "Levi & Korsinsky LLP has announced a securities lawsuit alert for investors of Savara Inc. (NASDAQ:SVRA). The class action seeks to recover losses for shareholders affected by alleged securities fraud between March 4, 2024, and May 23, 2025, primarily concerning misstatements abo", "url": "https://www.natlawreview.com/press-releases/securities-lawsuit-alert-savara-inc-svra-investors-contact-levi-korsinsky", "source_name": "The National Law Review", "published_at": "2026-06-28T18:10:47", "published_display": "28 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline", "summary": "Levi & Korsinsky LLP has issued a class action lawsuit alert for investors of Savara Inc. (NASDAQ: SVRA). The lawsuit, filed on behalf of shareholders who experienced losses between March 4, 2024, and May 23, 2025, alleges the company made false statements regarding its MOLBREEVI", "url": "https://natlawreview.com/press-releases/class-action-lawsuit-alert-levi-korsinsky-reminds-savara-inc-svra-investors", "source_name": "The National Law Review", "published_at": "2026-06-28T17:10:35", "published_display": "28 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025", "summary": "Levi & Korsinsky LLP has announced a class action securities lawsuit against Savara Inc. (SVRA) for alleged securities fraud between March 4, 2024, and May 23, 2025. The lawsuit claims Savara made false statements regarding its MOLBREEVI BLA treatment, suggesting insufficient che", "url": "https://natlawreview.com/press-releases/investors-savara-inc-svra-protect-your-rights-contact-levi-korsinsky", "source_name": "The National Law Review", "published_at": "2026-06-28T13:09:38", "published_display": "28 Jun 2026 13:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline", "summary": "", "url": "https://finance.yahoo.com/m/2b86fd68-bbf2-37fa-80e7-d463fe398998/what-savara-investors-should.html", "source_name": "Motley Fool", "published_at": "2026-06-27T15:34:09+00:00", "published_display": "27 Jun 2026 15:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SVRA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Savara, Inc. (SVRA) stock, based on analyst ratings and historical performance. It details current and historical stock prices, market capitalization, volatility, and future earnings estimates. The article also includes a Q&A ", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:09:40", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara, Inc. Actuals & Estimates (FWB:YB4P)", "summary": "This article provides an overview of Savara, Inc. (FWB: YB4P) including financial actuals and estimates, stock forecasts, and frequently asked questions. It details analyst price targets, historical stock performance, upcoming earnings dates, recent earnings per share, and revenu", "url": "https://www.tradingview.com/symbols/FWB-YB4P/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:40:55", "published_display": "26 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does the FDA's Priority Review Mean for Savara's MOLBREEVI", "summary": "Savara Inc. achieved a significant milestone with the FDA\u2019s Priority Review for its Biologics License Application (BLA) for MOLBREEVI, setting an August 22, 2026, PDUFA date. MOLBREEVI, targeting autoimmune pulmonary alveolar proteinosis (aPAP), addresses a rare lung disease with", "url": "https://www.kavout.com/market-lens/what-does-the-fda-s-priority-review-mean-for-savara-s-molbreevi", "source_name": "Kavout | AI", "published_at": "2026-06-26T05:09:40", "published_display": "26 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YB4P Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Savara, Inc. (YB4P) stock on the Frankfurt Stock Exchange. It includes analyst ratings, estimated future prices, historical stock performance, and key financial data such as earnings per share and revenue. The report also addre", "url": "https://www.tradingview.com/symbols/FWB-YB4P/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T02:40:43", "published_display": "26 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/savara-insider-sold-shares-worth-080412872.html", "source_name": "MT Newswires", "published_at": "2026-06-23T08:04:12+00:00", "published_display": "23 Jun 2026 08:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Savara Inc For: 22 June By Investing.com", "summary": "This article from Investing.com reports that Savara Inc. filed a Form 4 for insider transactions on June 22. The brief notice includes the stock symbol SVRA, which showed a 1.58% increase. The article provides minimal detail beyond the filing reference.", "url": "https://ng.investing.com/news/stock-market-news/form-4-savara-inc-for-22-june-93CH-2569129", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T01:34:00", "published_display": "23 Jun 2026 01:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara CFO David Lowrance sells $2.24m in company stock By Investing.com", "summary": "Savara CFO David Lowrance sold 394,528 shares of the company's common stock for approximately $2.24 million and acquired 580,187 shares through stock options for about $1.02 million. Following these transactions, including share dispositions for tax liabilities, Lowrance directly", "url": "https://ng.investing.com/news/stock-market-news/savara-cfo-david-lowrance-sells-224m-in-company-stock-93CH-2569125", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T00:39:54", "published_display": "23 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4", "summary": "Savara Inc.'s CFO, David L. Lowrance, exercised 580,187 stock options and sold 394,528 shares of common stock in an open-market transaction on June 22, 2026, at a weighted average price of $5.6813 per share. Additionally, 185,659 shares were withheld to cover tax obligations. Fol", "url": "https://www.stocktitan.net/sec-filings/SVRA/form-4-savara-inc-insider-trading-activity-857f635d422b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T00:10:57", "published_display": "23 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Savara Inc SEC Filing", "summary": "This SEC filing for Savara Inc. (SVRA) is a Form 144, indicating a notice of proposed sale of securities under Rule 144. The filing details the sale of 394,528 common shares with an aggregate market value of $2,229,000.00, through Raymond James & Associates on June 22, 2026, obta", "url": "https://www.stocktitan.net/sec-filings/SVRA/144-savara-inc-sec-filing-e54ca45c9c1b.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:10:57", "published_display": "22 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara CFO David Lowrance sells $2.24m in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNLUxhTko1M3hfX1JtVU9pdVpzTS1OQVp1T0JVeU5aclJUM0lraDZJSnY3RUVYUzIzSHFHMmhtS2lueEdKeTNxZEoyZ05MN0dYRnlHUHJCV01fbDk0RFNVdlE3SmpvZml5UUdoOFdHV0IySFhHS3p5NkZRdW4wdEpwdmcwSkpjRmNEOWtuZjktbW0xWVBsejlFQW9ZZ0tIVFl6S2NYOVBpbDZaakdyYmlCcldBZ05GMWFWLVE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Savara\u2019s Expanded Share Pool and CFO Shift Reframe Its Capital Strategy Narrative (SVRA)?", "summary": "Savara Inc. recently gained stockholder approval to double its authorized common shares to 600,000,000 and announced that CFO Dave Lowrance would depart due to health reasons, with COO Robert Lutz assuming the CFO role. These changes introduce capital flexibility and leadership c", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/does-savaras-expanded-share-pool-and-cfo-shift-reframe-its-c", "source_name": "Simply Wall Street", "published_at": "2026-06-20T19:39:30", "published_display": "20 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Savara Inc (SVRA), noting its current valuation score of 7.70, ranking 207 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -9.49, which is significantly below its recent high and above it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-svra/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:25", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Savara Inc (SVRA), focusing on its support and resistance levels, various technical indicators, and moving averages. As of June 16, 2026, SVRA has a price momentum score of 8.99 and is trading between a resistance level of 5.65 and a ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-svra/technical", "source_name": "TradingKey", "published_at": "2026-06-17T02:10:05", "published_display": "17 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Savara Inc (SVRA), assigning it a weak financial score of 5.22 out of 388 in the Biotechnology & Medical Research industry, indicating low operating efficiency. Key financial metrics such as cash and cash equivalents, total assets, to", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-svra/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T02:10:04", "published_display": "17 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara (SVRA) Proxy filing Summary", "summary": "Savara (SVRA) has scheduled its annual meeting for June 4, 2026, where shareholders will vote on board elections, an increase in authorized common stock, amendments to incentive plans, auditor ratification, and executive compensation. The company is preparing for the potential co", "url": "https://quartr.com/events/savara-inc-svra-proxy-filing_FeHkTZps", "source_name": "Quartr", "published_at": "2026-06-16T14:10:04", "published_display": "16 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Savara Inc (SVRA) has an earnings forecast score of 8.75, ranking high within its industry. Analysts have set an average price target of $10.25, with a consensus \"Buy\" rating based on 8 analysts. The company's previous quarter's EPS outperformed market expectations, and the next ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-svra/earnings", "source_name": "TradingKey", "published_at": "2026-06-15T12:39:04", "published_display": "15 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Announces New Employment Inducement Grant", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/savara-announces-employment-inducement-grant-200500419.html", "source_name": "Business Wire", "published_at": "2026-06-12T20:05:00+00:00", "published_display": "12 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara gives new hires stock tied to revenue milestone target", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQeEE3WnFQQ1V2TThzOXIyeElfdkEza1VnMDJ2cmNXY21KMTRmSm8xZlA5U2FYTER5WHhnOFp2cnZab2tBZXEwZ3RDWGJ6VDFJUUFOWGNJVTJQM25FUVozWmVuT0ZQWGdqZ01keVpkQTUxSzFmTE9tajNCQTVlUlpENkhHR2UxMkx5ak95SkdrX0VSOGcyVEhiamVLa29pQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxON0lGbzhsbEw1a19mWDJaSUppTzBFRU0zZkFXX2ZCUkx2UGNKOWwyRm5VbTJ0SHpIU0w5VW9jSDk1X3c3MnprTHJUQWFERDJTazVwbU04RDNOTk5GX0h5a3dTa3pseGFHVFFJQ3BNUDdpOV9NOXVIcG9JWlV4QUp6WjJ0b0tWUUladGJOYXRGTUlHTWhUN1NvNURudi1WSnVPVFZ1SUV3?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara (SVRA) expands share capacity and appoints Robert Lutz as CFO/COO", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNSkFMR3RXVV9PeUdlMlREVnNtSUJILVE5WVg3LTNKU2lZcDNVYlhVaV9ZWTZzTDMwc1NNbF9BaUpRN3BJUm1sS3Jab0RTckVfanhMa2VYdTVaemQ0UE0tcGJQTkxIN2dweDlBd0xRakZPQ1otQllGWmtzUUN5QjBDaUVlQ3djelFnb2Jyd3FRRmstTllhQ2NSM3VsZmtmYTUx?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Announces Chief Financial and Administrative Officer Transition", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPaDNlQW1GVHh2LWFacVlTVVZTZldjSnRWQUJDNHROc1o4LVBiZzdRc0VvbEZiVEFYampxVFA2VEVaQzRBdkJHSHVSWXNtbFMtRXUwaWowdFlndnl4bXlhbTB0clNfZzRwYjFTOGQxc0UweFNlLS1iWGYtRHY1ejB4YWhQTUVBX3ZMc2NZbWFhWUxzSnR0dXZRQzh2N1NEYjlyZ2dmUmh1YUhEc2xtbW43UG4tYjE0OEdtSkk0bFhQZlJUeldLelE?oc=5", "source_name": "Business Wire", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health-related exit at Savara: COO Robert Lutz takes finance role", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPczUydThjMVBPR2xHZjNzRDhVd3Y1ZVkzVXg0SGJFTWRQdy0tZE9rYXNTMjBlbTRvZ0Rocm1QajY0QlNJTERxXzE1NmFyS1l3ZE9sYmp5blc1eDMwazVSMzFMamptdDA5V2lQRjVkNTQ5ZUs2M2tzT2UyMkxqME1UMG40ekNwamhSbV9BaUl1UUlkNVFXZzhVS1BSa3FXSjE3aFU1Wk1nMVVNbjcwU2hqcjRRN04?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara: The Rare Disease Funnel Is Becoming A Commercial Asset (NASDAQ:SVRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxObWRPMUF3Ui1SalJLdmNockJlMml5TU9fM0tJQXN6UHcwOGdZcjZsSXZKRTFOQkZJcDBVemZqeDR3NVQ1bUhud0JEUkJqVEVhNWRQNV81RHVuVVZSWHRuU2tTbDB4aVVfQXNHd3dJbUJubVpMbVFVeUZuY0NtS0VubU5za1JyZ3hSWmhHN1RhWlgxRy1oNlRnVlhUMlIzV0JkMWVsdUszZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc. (SVRA) Reports Q1 Financial Results", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/savara-inc-svra-reports-q1-184322719.html", "source_name": "Insider Monkey", "published_at": "2026-05-22T18:43:22+00:00", "published_display": "22 May 2026 18:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rare lung disease trial: Savara drug cuts biomarkers tied to severity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNaW9rRXl5aC1NVFdZdXEtYURpeWRkYlh5cVFDUWdSamZMbkxOeHZBalo2VUI5cGNWWlZBQTBtd2FGblZyaTB3bVU5ZzZsZE1acFQzOXpTZE9EazhGbWNrNTBUZ1BZMWJOYVMtWkdwRGQ1REhJTzVvemhDUURNQTRtcDdtT1BjMlU4ajF0dWFVZnNzVnBwVFRVY1EtRTNiOHhkUVZxOVY2UHBncnNqRWlPYks3VmpUNXM?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Savara Q1 Loss Widens", "summary": "", "url": "https://finance.yahoo.com/news/savara-q1-loss-widens-203302185.html", "source_name": "MT Newswires", "published_at": "2026-05-12T20:33:02+00:00", "published_display": "12 May 2026 20:33", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOWlpJMkplcFJnemlBQXpTbTYzSXR1X3Q5TEtheldUTExYT1RaWXNRZzJKUHl1MElCd2Z0RVdqZldVX0JnQktJU0gwTkRJT3F3WkEtc1prSG9mdWstcUJOck5FUGZzTkR6b3V2Ry01M2xRWS05UzNUaDljakxORVlMZEJna0ZQRHJKaGtJQlhlUEE4aVpQN08tay1zejRrUWNIeVVENVB3Yw?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara\u2019s FDA Review Extension Keeps Molgramostim Thesis Intact But Delayed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Savara gives 24 new hires stock awards tied to tenure and revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNZHJHTTNLbG50T3JzMVU3aWxiNWpzX0JGRWw0VG1QV1BUQWZfeG1YUnNYZzFCVDNMdjBDT0xJM1NPYXBZWEt3Z1g1OEJ6blhEZXZkcUlxWFZ4M3U0bFpQYUtCOHRtZjUyQkRpYVpKVXVWa212M3l3T0JzV0VELWpjRnlBMm1heWRCN0hqaWcybmRHLXM3STRRdjlydXdSQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Extends Review of Savara\u2019s Molgramostim BLA for PAP", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObFQwa3BJdDdSYVoyU0pDbDdHQmx0bE93c21KMy02S3k2MXB3UWl2dGpTMkdrRHF1d2JHWVdvQ0NPcmZtckFwV2ZUa25UUUM4R0hYbU1tRDdLbURuQkhIY2RlaXZrVGZQZS1HdlhrbW1pbWpPXy1VMS10NHQteEI5RHMzRlFyWnkzWEdFYWZXSUl1VFlBZEl1OTR3bWJTWk0?oc=5", "source_name": "BioPharm International", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara's rare lung disease drug gets 3 more months at FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNeWtMSlBzWHRtYnd1eTJaSjJVSVAzZ0JCcS02aVhSdjhaTzZxVHk4bkFDOU5vcjRMVFFGOUVQUG5tV0F1MjlJR1hlTS1iYVpNTGZHbkRaUDByMFJoN0RIczM3VEhDWWtmTmhiWjdzODlPQ0pYeFBrWXNWWGN2QmpJVm5jTEFMMnpacHVlUEMxdlJra0JTZjFYclp2cGdXVlEzT1lhMFpJbWtTTmpiV0pkX3RGQ05jbG1TaE5laXd3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE5hZnA1c1J3QXNkbFhxbGxvd1hyYm1KYlNwVG1kcm1UaXVaSkJhVC1mOHJBUjE2ZlJsc19QVmRSTEwwUXNIRE1yNUJKUXN3b2NySy1PVHVTc1ZucHB0eTM5SGE0MlN2QVlqeTNnVzJHWFlyV0tY?oc=5", "source_name": "Market source", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Stock: A High-Risk Opportunity (NASDAQ:SVRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE0ydnVjRklUSUdoQ05CNEdULTF4Sk01TlpUenk3cGpOY24xM3p5dzZ3blMxa0dSbHFrWTV5S2JUVDlPblpHdFljUmR0MGVyTnNqaVV1cmJPd2lUQVFZR0FHMjFUQzU0aWw5QzZiNjlMbEc2ZmpJMG1xUA?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-16T08:00:00+00:00", "published_display": "16 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxNMlJERU5WRXpOdXNOc0VXS29IWUVqdjhKdWVMaDE2WjUtWElRcUlYaDRWSjVBNW1LQW5XRXhPSlZiTUJaM1BBd1hmQTRGSEJLOEFqWFRLYVo2c1ZERDBHQ2pBMFpuU0hwS281MmkwYzhWakxDcktGOWhtbEFkSE5xcmJra2tBdjZXZEhZSWE4aUlkOVZCYWJBcm1ubllmVDZCLXp1c2Z4dW55RWg4b2MtUDFFYldQSkNMdllBa2xEZU9Uc2dFUGFsWXcxMmxZcjZtTDhhdEZ5R0ZneTFQVC1qV2xyNVJoZGdRRDBzODNB?oc=5", "source_name": "Business Wire", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara (SVRA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE00VF9vdkRYMEtPV3BpeF94SGJpbmRQY3dqeDhxVnZnS0NZV1JEWXpOaEFXU0M5UVE1Z296RlQ4c3g1ZlJ4aDA4ZFE2MEFRdm1kMmxv?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:55:00+00:00", "published_display": "24 Apr 2025 23:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Begins Rolling BLA for Molbreevi for Rare Lung Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOM2hlZUQ1MWVwazZRN09mZHpFdjhGSVozUWJCVzVtY1FHZ3I2ejFHWGQ3bzlfalpFYlZfZEltMVpVWlBqclZ1WFlTU1RpNWl2MXBqSVZFNk5JWkNrdHZBUzl6N0ZIeTVyNDI0d0xRdkRsVWJPUDhrU29EMHE2VUtQbjhKa25Nb2NkWndSMHgyOGdHN0F4SVVFeUdZLVJRZm1kdFBPb1FGZ29Sam4xRWc?oc=5", "source_name": "Managed Healthcare Executive", "published_at": "2024-12-20T08:00:00+00:00", "published_display": "20 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Join Class Action to Recover Losses from Savara Inc. (SVRA) - Contact Levi & Korsinsky Before November 7, 2025", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Savara Inc. (SVRA) on behalf of shareholders who suffered losses due to alleged securities fraud between March 4, 2024, and May 23, 2025. The lawsuit claims Savara made false statements and concealed issues ", "url": "https://www.natlawreview.com/press-releases/join-class-action-recover-losses-savara-inc-svra-contact-levi-korsinsky", "source_name": "The National Law Review", "published_at": "2026-07-14T17:42:44", "published_display": "14 Jul 2026 17:42", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara (SVRA) Stock May Trade At A Premium On Pipeline Expectations", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara stock. Thin-source profile holds the focus.", "summary": "Savara Inc. (SVRA) continues to focus on its rare-disease pipeline and Nasdaq listing, with its lead program being molgramostim inhalation therapy for autoimmune pulmonary alveolar proteinosis. Despite the absence of new market catalysts, the company's development pipeline and fi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/savara-stock-thin-source-profile-holds-the-focus/69715953", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:32:08", "published_display": "07 Jul 2026 16:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "This article displays the \"Price to earnings forward\" value for Savara, Inc. (NASDAQ: SVRA) on TradingView. It indicates that the period value and change are displayed, and states that the information is \"Made by humans.\"", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T10:09:34", "published_display": "05 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "This article provides a financial snapshot for Savara, Inc. (NASDAQ: SVRA), focusing on its enterprise value to EBIT forward. It indicates whether there have been changes in this period and by what percentage. The data is supported by various financial services and is presented v", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T23:40:34", "published_display": "04 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "This article displays the Enterprise Value to EBITDA forward for Savara, Inc. (NASDAQ: SVRA) on TradingView. It indicates that the market was closed at the time of viewing, with no trades reported. The content is primarily a data point without further analytical text.", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T05:11:11", "published_display": "04 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc focuses on respiratory drug development as investors watch clinical progress", "summary": "Savara Inc. is a clinical-stage biopharmaceutical company specializing in developing inhaled therapies for rare respiratory diseases. The company's strategy involves focusing on conditions with high unmet medical needs, pursuing orphan-drug designations, and advancing its pipelin", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/savara-inc-focuses-on-respiratory-drug-development-as-investors-watch/69682070", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T18:09:51", "published_display": "03 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "This article provides financial information for Savara, Inc. (NASDAQ: SVRA), specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section of a larger financial data display, indicating the period and value of this metric. It originates f", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T11:41:14", "published_display": "02 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "This page provides financial information for Savara, Inc. (NASDAQ: SVRA), specifically focusing on its price-to-sales forward metric. It appears to be a financial data snippet from TradingView, offering a quick overview of this particular financial ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T06:09:42", "published_display": "01 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Savara, Inc. \u2013 NASDAQ:SVRA", "summary": "The article focuses on the enterprise value to revenue forward metric for Savara, Inc. (NASDAQ: SVRA). It appears to be a stub or a placeholder, as no specific financial data or analysis is presented in the provided content, only the title and navigation elements.", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T13:41:53", "published_display": "30 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline", "summary": "Levi & Korsinsky LLP has announced a class action lawsuit against Savara Inc. (NASDAQ:SVRA), reminding investors of the November 7, 2025 deadline to join. The lawsuit alleges that Savara made false and misleading statements between March 4, 2024, and May 23, 2025, regarding the r", "url": "https://www.natlawreview.com/press-releases/savara-inc-svra-class-action-lawsuit-levi-korsinsky-reminds-investors", "source_name": "The National Law Review", "published_at": "2026-06-30T06:39:11", "published_display": "30 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Notifies Savara Inc. (SVRA) Investors - Lead Plaintiff Deadline on November 7, 2025", "summary": "Levi & Korsinsky has announced a class action securities lawsuit against Savara Inc. (SVRA), urging investors who suffered losses between March 4, 2024, and May 23, 2025, to come forward by the lead plaintiff deadline of November 7, 2025. The lawsuit alleges that Savara made fals", "url": "https://natlawreview.com/press-releases/levi-korsinsky-notifies-savara-inc-svra-investors-lead-plaintiff-deadline", "source_name": "The National Law Review", "published_at": "2026-06-28T19:39:41", "published_display": "28 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Lawsuit Alert: Savara Inc. (SVRA) Investors - Contact Levi & Korsinsky Before November 7, 2025", "summary": "Levi & Korsinsky LLP has announced a securities lawsuit alert for investors of Savara Inc. (NASDAQ:SVRA). The class action seeks to recover losses for shareholders affected by alleged securities fraud between March 4, 2024, and May 23, 2025, primarily concerning misstatements abo", "url": "https://www.natlawreview.com/press-releases/securities-lawsuit-alert-savara-inc-svra-investors-contact-levi-korsinsky", "source_name": "The National Law Review", "published_at": "2026-06-28T18:10:47", "published_display": "28 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline", "summary": "Levi & Korsinsky LLP has issued a class action lawsuit alert for investors of Savara Inc. (NASDAQ: SVRA). The lawsuit, filed on behalf of shareholders who experienced losses between March 4, 2024, and May 23, 2025, alleges the company made false statements regarding its MOLBREEVI", "url": "https://natlawreview.com/press-releases/class-action-lawsuit-alert-levi-korsinsky-reminds-savara-inc-svra-investors", "source_name": "The National Law Review", "published_at": "2026-06-28T17:10:35", "published_display": "28 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025", "summary": "Levi & Korsinsky LLP has announced a class action securities lawsuit against Savara Inc. (SVRA) for alleged securities fraud between March 4, 2024, and May 23, 2025. The lawsuit claims Savara made false statements regarding its MOLBREEVI BLA treatment, suggesting insufficient che", "url": "https://natlawreview.com/press-releases/investors-savara-inc-svra-protect-your-rights-contact-levi-korsinsky", "source_name": "The National Law Review", "published_at": "2026-06-28T13:09:38", "published_display": "28 Jun 2026 13:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline", "summary": "", "url": "https://finance.yahoo.com/m/2b86fd68-bbf2-37fa-80e7-d463fe398998/what-savara-investors-should.html", "source_name": "Motley Fool", "published_at": "2026-06-27T15:34:09+00:00", "published_display": "27 Jun 2026 15:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SVRA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Savara, Inc. (SVRA) stock, based on analyst ratings and historical performance. It details current and historical stock prices, market capitalization, volatility, and future earnings estimates. The article also includes a Q&A ", "url": "https://www.tradingview.com/symbols/NASDAQ-SVRA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:09:40", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara, Inc. Actuals & Estimates (FWB:YB4P)", "summary": "This article provides an overview of Savara, Inc. (FWB: YB4P) including financial actuals and estimates, stock forecasts, and frequently asked questions. It details analyst price targets, historical stock performance, upcoming earnings dates, recent earnings per share, and revenu", "url": "https://www.tradingview.com/symbols/FWB-YB4P/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:40:55", "published_display": "26 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does the FDA's Priority Review Mean for Savara's MOLBREEVI", "summary": "Savara Inc. achieved a significant milestone with the FDA\u2019s Priority Review for its Biologics License Application (BLA) for MOLBREEVI, setting an August 22, 2026, PDUFA date. MOLBREEVI, targeting autoimmune pulmonary alveolar proteinosis (aPAP), addresses a rare lung disease with", "url": "https://www.kavout.com/market-lens/what-does-the-fda-s-priority-review-mean-for-savara-s-molbreevi", "source_name": "Kavout | AI", "published_at": "2026-06-26T05:09:40", "published_display": "26 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YB4P Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Savara, Inc. (YB4P) stock on the Frankfurt Stock Exchange. It includes analyst ratings, estimated future prices, historical stock performance, and key financial data such as earnings per share and revenue. The report also addre", "url": "https://www.tradingview.com/symbols/FWB-YB4P/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T02:40:43", "published_display": "26 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/savara-insider-sold-shares-worth-080412872.html", "source_name": "MT Newswires", "published_at": "2026-06-23T08:04:12+00:00", "published_display": "23 Jun 2026 08:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Savara Inc For: 22 June By Investing.com", "summary": "This article from Investing.com reports that Savara Inc. filed a Form 4 for insider transactions on June 22. The brief notice includes the stock symbol SVRA, which showed a 1.58% increase. The article provides minimal detail beyond the filing reference.", "url": "https://ng.investing.com/news/stock-market-news/form-4-savara-inc-for-22-june-93CH-2569129", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T01:34:00", "published_display": "23 Jun 2026 01:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara CFO David Lowrance sells $2.24m in company stock By Investing.com", "summary": "Savara CFO David Lowrance sold 394,528 shares of the company's common stock for approximately $2.24 million and acquired 580,187 shares through stock options for about $1.02 million. Following these transactions, including share dispositions for tax liabilities, Lowrance directly", "url": "https://ng.investing.com/news/stock-market-news/savara-cfo-david-lowrance-sells-224m-in-company-stock-93CH-2569125", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T00:39:54", "published_display": "23 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4", "summary": "Savara Inc.'s CFO, David L. Lowrance, exercised 580,187 stock options and sold 394,528 shares of common stock in an open-market transaction on June 22, 2026, at a weighted average price of $5.6813 per share. Additionally, 185,659 shares were withheld to cover tax obligations. Fol", "url": "https://www.stocktitan.net/sec-filings/SVRA/form-4-savara-inc-insider-trading-activity-857f635d422b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T00:10:57", "published_display": "23 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Savara Inc SEC Filing", "summary": "This SEC filing for Savara Inc. (SVRA) is a Form 144, indicating a notice of proposed sale of securities under Rule 144. The filing details the sale of 394,528 common shares with an aggregate market value of $2,229,000.00, through Raymond James & Associates on June 22, 2026, obta", "url": "https://www.stocktitan.net/sec-filings/SVRA/144-savara-inc-sec-filing-e54ca45c9c1b.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:10:57", "published_display": "22 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara CFO David Lowrance sells $2.24m in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNLUxhTko1M3hfX1JtVU9pdVpzTS1OQVp1T0JVeU5aclJUM0lraDZJSnY3RUVYUzIzSHFHMmhtS2lueEdKeTNxZEoyZ05MN0dYRnlHUHJCV01fbDk0RFNVdlE3SmpvZml5UUdoOFdHV0IySFhHS3p5NkZRdW4wdEpwdmcwSkpjRmNEOWtuZjktbW0xWVBsejlFQW9ZZ0tIVFl6S2NYOVBpbDZaakdyYmlCcldBZ05GMWFWLVE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Savara\u2019s Expanded Share Pool and CFO Shift Reframe Its Capital Strategy Narrative (SVRA)?", "summary": "Savara Inc. recently gained stockholder approval to double its authorized common shares to 600,000,000 and announced that CFO Dave Lowrance would depart due to health reasons, with COO Robert Lutz assuming the CFO role. These changes introduce capital flexibility and leadership c", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/does-savaras-expanded-share-pool-and-cfo-shift-reframe-its-c", "source_name": "Simply Wall Street", "published_at": "2026-06-20T19:39:30", "published_display": "20 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Savara Inc (SVRA), noting its current valuation score of 7.70, ranking 207 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -9.49, which is significantly below its recent high and above it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-svra/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:25", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Savara Inc (SVRA), focusing on its support and resistance levels, various technical indicators, and moving averages. As of June 16, 2026, SVRA has a price momentum score of 8.99 and is trading between a resistance level of 5.65 and a ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-svra/technical", "source_name": "TradingKey", "published_at": "2026-06-17T02:10:05", "published_display": "17 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Savara Inc (SVRA), assigning it a weak financial score of 5.22 out of 388 in the Biotechnology & Medical Research industry, indicating low operating efficiency. Key financial metrics such as cash and cash equivalents, total assets, to", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-svra/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T02:10:04", "published_display": "17 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara (SVRA) Proxy filing Summary", "summary": "Savara (SVRA) has scheduled its annual meeting for June 4, 2026, where shareholders will vote on board elections, an increase in authorized common stock, amendments to incentive plans, auditor ratification, and executive compensation. The company is preparing for the potential co", "url": "https://quartr.com/events/savara-inc-svra-proxy-filing_FeHkTZps", "source_name": "Quartr", "published_at": "2026-06-16T14:10:04", "published_display": "16 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Savara Inc (SVRA) has an earnings forecast score of 8.75, ranking high within its industry. Analysts have set an average price target of $10.25, with a consensus \"Buy\" rating based on 8 analysts. The company's previous quarter's EPS outperformed market expectations, and the next ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-svra/earnings", "source_name": "TradingKey", "published_at": "2026-06-15T12:39:04", "published_display": "15 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Announces New Employment Inducement Grant", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/savara-announces-employment-inducement-grant-200500419.html", "source_name": "Business Wire", "published_at": "2026-06-12T20:05:00+00:00", "published_display": "12 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara gives new hires stock tied to revenue milestone target", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQeEE3WnFQQ1V2TThzOXIyeElfdkEza1VnMDJ2cmNXY21KMTRmSm8xZlA5U2FYTER5WHhnOFp2cnZab2tBZXEwZ3RDWGJ6VDFJUUFOWGNJVTJQM25FUVozWmVuT0ZQWGdqZ01keVpkQTUxSzFmTE9tajNCQTVlUlpENkhHR2UxMkx5ak95SkdrX0VSOGcyVEhiamVLa29pQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxON0lGbzhsbEw1a19mWDJaSUppTzBFRU0zZkFXX2ZCUkx2UGNKOWwyRm5VbTJ0SHpIU0w5VW9jSDk1X3c3MnprTHJUQWFERDJTazVwbU04RDNOTk5GX0h5a3dTa3pseGFHVFFJQ3BNUDdpOV9NOXVIcG9JWlV4QUp6WjJ0b0tWUUladGJOYXRGTUlHTWhUN1NvNURudi1WSnVPVFZ1SUV3?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara (SVRA) expands share capacity and appoints Robert Lutz as CFO/COO", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNSkFMR3RXVV9PeUdlMlREVnNtSUJILVE5WVg3LTNKU2lZcDNVYlhVaV9ZWTZzTDMwc1NNbF9BaUpRN3BJUm1sS3Jab0RTckVfanhMa2VYdTVaemQ0UE0tcGJQTkxIN2dweDlBd0xRakZPQ1otQllGWmtzUUN5QjBDaUVlQ3djelFnb2Jyd3FRRmstTllhQ2NSM3VsZmtmYTUx?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Announces Chief Financial and Administrative Officer Transition", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPaDNlQW1GVHh2LWFacVlTVVZTZldjSnRWQUJDNHROc1o4LVBiZzdRc0VvbEZiVEFYampxVFA2VEVaQzRBdkJHSHVSWXNtbFMtRXUwaWowdFlndnl4bXlhbTB0clNfZzRwYjFTOGQxc0UweFNlLS1iWGYtRHY1ejB4YWhQTUVBX3ZMc2NZbWFhWUxzSnR0dXZRQzh2N1NEYjlyZ2dmUmh1YUhEc2xtbW43UG4tYjE0OEdtSkk0bFhQZlJUeldLelE?oc=5", "source_name": "Business Wire", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health-related exit at Savara: COO Robert Lutz takes finance role", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPczUydThjMVBPR2xHZjNzRDhVd3Y1ZVkzVXg0SGJFTWRQdy0tZE9rYXNTMjBlbTRvZ0Rocm1QajY0QlNJTERxXzE1NmFyS1l3ZE9sYmp5blc1eDMwazVSMzFMamptdDA5V2lQRjVkNTQ5ZUs2M2tzT2UyMkxqME1UMG40ekNwamhSbV9BaUl1UUlkNVFXZzhVS1BSa3FXSjE3aFU1Wk1nMVVNbjcwU2hqcjRRN04?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara: The Rare Disease Funnel Is Becoming A Commercial Asset (NASDAQ:SVRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxObWRPMUF3Ui1SalJLdmNockJlMml5TU9fM0tJQXN6UHcwOGdZcjZsSXZKRTFOQkZJcDBVemZqeDR3NVQ1bUhud0JEUkJqVEVhNWRQNV81RHVuVVZSWHRuU2tTbDB4aVVfQXNHd3dJbUJubVpMbVFVeUZuY0NtS0VubU5za1JyZ3hSWmhHN1RhWlgxRy1oNlRnVlhUMlIzV0JkMWVsdUszZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Inc. (SVRA) Reports Q1 Financial Results", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/savara-inc-svra-reports-q1-184322719.html", "source_name": "Insider Monkey", "published_at": "2026-05-22T18:43:22+00:00", "published_display": "22 May 2026 18:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rare lung disease trial: Savara drug cuts biomarkers tied to severity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNaW9rRXl5aC1NVFdZdXEtYURpeWRkYlh5cVFDUWdSamZMbkxOeHZBalo2VUI5cGNWWlZBQTBtd2FGblZyaTB3bVU5ZzZsZE1acFQzOXpTZE9EazhGbWNrNTBUZ1BZMWJOYVMtWkdwRGQ1REhJTzVvemhDUURNQTRtcDdtT1BjMlU4ajF0dWFVZnNzVnBwVFRVY1EtRTNiOHhkUVZxOVY2UHBncnNqRWlPYks3VmpUNXM?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Q1 Loss Widens", "summary": "", "url": "https://finance.yahoo.com/news/savara-q1-loss-widens-203302185.html", "source_name": "MT Newswires", "published_at": "2026-05-12T20:33:02+00:00", "published_display": "12 May 2026 20:33", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOWlpJMkplcFJnemlBQXpTbTYzSXR1X3Q5TEtheldUTExYT1RaWXNRZzJKUHl1MElCd2Z0RVdqZldVX0JnQktJU0gwTkRJT3F3WkEtc1prSG9mdWstcUJOck5FUGZzTkR6b3V2Ry01M2xRWS05UzNUaDljakxORVlMZEJna0ZQRHJKaGtJQlhlUEE4aVpQN08tay1zejRrUWNIeVVENVB3Yw?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara\u2019s FDA Review Extension Keeps Molgramostim Thesis Intact But Delayed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara gives 24 new hires stock awards tied to tenure and revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNZHJHTTNLbG50T3JzMVU3aWxiNWpzX0JGRWw0VG1QV1BUQWZfeG1YUnNYZzFCVDNMdjBDT0xJM1NPYXBZWEt3Z1g1OEJ6blhEZXZkcUlxWFZ4M3U0bFpQYUtCOHRtZjUyQkRpYVpKVXVWa212M3l3T0JzV0VELWpjRnlBMm1heWRCN0hqaWcybmRHLXM3STRRdjlydXdSQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Extends Review of Savara\u2019s Molgramostim BLA for PAP", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObFQwa3BJdDdSYVoyU0pDbDdHQmx0bE93c21KMy02S3k2MXB3UWl2dGpTMkdrRHF1d2JHWVdvQ0NPcmZtckFwV2ZUa25UUUM4R0hYbU1tRDdLbURuQkhIY2RlaXZrVGZQZS1HdlhrbW1pbWpPXy1VMS10NHQteEI5RHMzRlFyWnkzWEdFYWZXSUl1VFlBZEl1OTR3bWJTWk0?oc=5", "source_name": "BioPharm International", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara's rare lung disease drug gets 3 more months at FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNeWtMSlBzWHRtYnd1eTJaSjJVSVAzZ0JCcS02aVhSdjhaTzZxVHk4bkFDOU5vcjRMVFFGOUVQUG5tV0F1MjlJR1hlTS1iYVpNTGZHbkRaUDByMFJoN0RIczM3VEhDWWtmTmhiWjdzODlPQ0pYeFBrWXNWWGN2QmpJVm5jTEFMMnpacHVlUEMxdlJra0JTZjFYclp2cGdXVlEzT1lhMFpJbWtTTmpiV0pkX3RGQ05jbG1TaE5laXd3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE5hZnA1c1J3QXNkbFhxbGxvd1hyYm1KYlNwVG1kcm1UaXVaSkJhVC1mOHJBUjE2ZlJsc19QVmRSTEwwUXNIRE1yNUJKUXN3b2NySy1PVHVTc1ZucHB0eTM5SGE0MlN2QVlqeTNnVzJHWFlyV0tY?oc=5", "source_name": "Market source", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Stock: A High-Risk Opportunity (NASDAQ:SVRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE0ydnVjRklUSUdoQ05CNEdULTF4Sk01TlpUenk3cGpOY24xM3p5dzZ3blMxa0dSbHFrWTV5S2JUVDlPblpHdFljUmR0MGVyTnNqaVV1cmJPd2lUQVFZR0FHMjFUQzU0aWw5QzZiNjlMbEc2ZmpJMG1xUA?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-16T08:00:00+00:00", "published_display": "16 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxNMlJERU5WRXpOdXNOc0VXS29IWUVqdjhKdWVMaDE2WjUtWElRcUlYaDRWSjVBNW1LQW5XRXhPSlZiTUJaM1BBd1hmQTRGSEJLOEFqWFRLYVo2c1ZERDBHQ2pBMFpuU0hwS281MmkwYzhWakxDcktGOWhtbEFkSE5xcmJra2tBdjZXZEhZSWE4aUlkOVZCYWJBcm1ubllmVDZCLXp1c2Z4dW55RWg4b2MtUDFFYldQSkNMdllBa2xEZU9Uc2dFUGFsWXcxMmxZcjZtTDhhdEZ5R0ZneTFQVC1qV2xyNVJoZGdRRDBzODNB?oc=5", "source_name": "Business Wire", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara (SVRA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE00VF9vdkRYMEtPV3BpeF94SGJpbmRQY3dqeDhxVnZnS0NZV1JEWXpOaEFXU0M5UVE1Z296RlQ4c3g1ZlJ4aDA4ZFE2MEFRdm1kMmxv?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:55:00+00:00", "published_display": "24 Apr 2025 23:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Savara Begins Rolling BLA for Molbreevi for Rare Lung Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOM2hlZUQ1MWVwazZRN09mZHpFdjhGSVozUWJCVzVtY1FHZ3I2ejFHWGQ3bzlfalpFYlZfZEltMVpVWlBqclZ1WFlTU1RpNWl2MXBqSVZFNk5JWkNrdHZBUzl6N0ZIeTVyNDI0d0xRdkRsVWJPUDhrU29EMHE2VUtQbjhKa25Nb2NkWndSMHgyOGdHN0F4SVVFeUdZLVJRZm1kdFBPb1FGZ29Sam4xRWc?oc=5", "source_name": "Managed Healthcare Executive", "published_at": "2024-12-20T08:00:00+00:00", "published_display": "20 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 62, "sentiment_summary": {"positive": 7, "negative": 10, "neutral": 45, "score": 48, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 21.05, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 5.52, "latest_week": "2026-07-17", "one_week_move": -8.5, "four_week_move": 0.4, "twelve_week_move": 7.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.741315, "market_dynamics_buy_signal": false, "relative_strength": 1.792312, "fair_value_gap": 34.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.1797, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.5% over one week, +0.4% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 9}, {"label": "Stock Titan", "count": 9}, {"label": "The National Law Review", "count": 6}, {"label": "simplywall.st", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "Business Wire", "count": 3}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 16}, {"label": "Regulatory and legal", "count": 7}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-8.5% over one week, +0.4% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Join Class Action to Recover Losses from Savara Inc. (SVRA) - Contact Levi & Korsinsky Before November 7, 2025"}], "updated_at": "2026-07-19T02:38:47.952378+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}